Role of nuclear receptor coregulators in metabolism

Expert Review of Endocrinology and Metabolism

Volumn 2, Issue 6, 2007, Pages 797-807

  Morganstein, Daniel L ^a   Parker, Malcolm G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adipocyte; Metabolism; Nuclear receptor; PGC 1 ; PGC 1 ; RIP140; Skeletal muscle

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BILE ACID; CELL NUCLEUS RECEPTOR; CELL NUCLEUS RECEPTOR COREGULATOR; CHOLESTEROL; FAT; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; LIGAND; MURAGLITAZAR; NUCLEAR RECEPTOR COREPRESSOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PIOGLITAZONE; RECEPTOR INTERACTING PROTEIN 140; ROSIGLITAZONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG FATALITY; DYSLIPIDEMIA; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; WEIGHT GAIN;

EID: 36148989540     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.2.6.797     Document Type: Review

References (78)

1. Haslam DW, James WP. Obesity. Lancet 366(9492), 1197-1209 (2005).
2. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 366(9491), 1059-1062 (2005).
3. Seidell JC. Obesity as a health problem. In: Oxford Textbook of Endocrinology and DIabetes. Wass JAH, Shalet SM (Eds). Oxford University Press, Oxford, UK 1611-1614 (2002).
4. van Harmelen V, Skurk T, Rohrig K et al. Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women. Int. J. Obes. Relat. Metab. Disord. 27(8), 889-895 (2003).
5. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am. J. Physiol. Endocrinol. Metab. 255(6), E769-E774 (1988).
6. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin. Endocrinol. (Oxford) 64(4), 355-365 (2006).
7. Robinson-Rechavi M, Garcia HE, Laudet V. The nuclear receptor superfamily. J. Cell. Sci. 116(4), 585-586 (2003).
8. Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell 83(6), 835-839 (1995).
9. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physoil. 65, 261-311 (2003).
10. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137(1), 354-366 (1996).
11. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl Acad. Sci. USA 91(23), 11012-11016 (1994).
12. Fürnsinn C, Willson T, Brunmair B. Peroxisome proliferator-activated receptor-+Y, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 50(1), 8-17 (2007).
13. Wang YX, Lee CH, Tiep S et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113(2), 159-170 (2003).
14. Rosen ED, Sarraf P, Troy AE et al. PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4(4), 611-617 (1999).
15. Sprecher DL, Massien C, Pearce G et al. Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arterioscler. Thromb. Vasc. Biol. 27(2), 359-365 (2007).
16. Giguere V. To ERR in the estrogen pathway. Trends Endocrinol. Metab. 13(5), 220-225 (2002).
17. Huss JM, Torra IP, Staels B, Giguere V, Kelly DP. Estrogen-related receptor α directs peroxisome proliferator-activated receptor α signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 24(20), 9079-9091 (2004).
18. Villena JA, Hock MB, Chang WY et al. Orphan nuclear receptor estrogen-related receptor α is essential for adaptive thermogenesis. Proc. Natl Acad. Sci USA 104(4), 1418-1423 (2007).
19. Kallen J, Schlaeppi J-M, Bitsch F et al. Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor α (ERRα): crystal structure of ERRα ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1α. J. Biol. Chem. 279(47), 49330-49337 (2004).
20. Willy PJ, Murray IR, Qian J et al. Regulation of PPARγ coactivator 1α (PGC-1α) signaling by an estrogen-related receptor α (ERRα) ligand. Proc. Natl Acad. Sci. USA 101(24), 8912-8917 (2004).
21. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108(4), 465-474 (2002).
22. Puigserver P, Wu Z, Park CW et al. A cold inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92(6), 829-839 (1998).
23. Lin J, Puigserver R Donovan J, Tarr P. Spiegelman BM. Peroxisome proliferator-activated receptor 2c coactivator 1β (PGC-1β), a novel PGC-1-related transcription coactivator associated with host cell factor. J. Biol. Chem. 277(3), 1645-1648 (2002).
24. Andersson U, Scarpulla RC. PGC-1-related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor 1 - dependent transcription in mammalian cells. Mol. Cell. Biol. 21(11), 3738-3749 (2001).
25. Cavailles V, Dauvois S, L'Horset F et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 14(15), 3741-3751 (1995).
26. L'Horset F, Dauvois S, Heery D, Cavailles V, Parker M. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol. Cell. Biol. 16(11), 6029-6036 (1996).
27. Heery DM, Hoare S, Hussain S, Parker MG, Sheppard H. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J. Biol. Chem. 276(9), 6695-6702 (2001).
28. Hu X, Chen Y, Farooqui M et al. Suppressive effect of receptor-interacting protein 140 on coregulator binding to retinoic acid receptor complexes, histone-modifying enzyme activity, and gene activation. J. Biol. Chem. 279(1), 319-325 (2004).
29. Christian M, Tullet JM, Parker MG. Characterization of four autonomous repression domains in the corepressor receptor interacting protein 140. J. Biol. Chem. 279(15), 15645-15651-(2004).
30. Puigserver P, Adelmant G, Wu Z et al. Activation of PPAR coactivator-1 through transcription factor docking. Science 286(5443), 1368-1371 (1999).
31. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84(1), 277-359 (2004).
32. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 293(2), E444-F452 (2007).
33. Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54(5), 1392-1399 (2005).
34. Nedergaard J, Petrovic N, Lindgren EM, Jacobsson A, Cannon B. PPARγ in the control of brown adipocyte differentiation. Biochim. Biophys. Acta 1740(2), 293-304 (2005).
35. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor γ. Mol. Cell. Biol. 16(7), 3410-3419 (1996).
36. Tiraby C, Tavernier G, Lefort C et al. Acquirement of brown fat cell features by human white adipocytes. J. Biol. Chem. 278(35), 33370-33376 (2003).
37. Uldry M, Yang W, St-Pierre J et al. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab. 3(5), 333-341 (2006).
38. Leone TC, Lehman JJ, Finck BN et al. PGC-1 &a; deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3(4), e101 (2005).
39. Lin J, Wu PH, Tarr PT et al. Defects in adaptive-energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell 119(1), 121-135 (2004).
40. del Mar Gonzalez-Barroso M, Pecqueur C, Gelly C et al. Transcriptional activation of the human UCP1 gene in a rodent cell line synergism of retinoids, isoproterenol, and thiozolidinedione is mediated by a multipartite response element. J. Biol. Chem. 275(41), 31722-31732 (2000).
41. Huss JM, Kopp RP, Kelly DP. Peroxisome proliferator-activated receptor coactivator-1α (PGC-1α) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-α and -γ. Identification of novel leucine-rich interaction motif within PGC-1α. J. Biol. Chem. 277(43), 40265-40274 (2002).
42. Schreiber SN, Knutti D, Brogli K, Uhlmann T, Krain A. The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor α (ERRα). J. Biol. Chem. 278(11), 9013-9018 (2003).
43. Lelliott CJ, Medina-Gomez G, Petrovic N et al. Ablation of PGC-1&β; results in defective mitochondrial activity thermogenesis, hepatic function, and cardiac performance. PLoS Biol. 4(11), e369 (2006).
44. Leonardsson G, Steel JH, Christian M et al. Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc. Natl Acad. Sci. USA 101 (22), 8437-8442 (2004).
45. Christian M, Kiskinis E, Debevec D et al. RIP140-targeted repression of gene expression in adipocytes. Mol. Cell. Biol. 25(21), 9383-9391 (2005).
46. Powelka AM, Seth A, Virbasius JV et al. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. J. Clin. Invest. 116(1), 125-136 (2006).
47. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with Type 2 diabetes. N. Engl. J. Med. 350(7), 664-671 (2004).
48. Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 75(1), 19-37 (2006).
49. Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol. Rev. 76(2), 371-423 (1996).
50. Larsson L, Edstrom L, Lindegren B, Gorza L, Schiaffino S. MHC composition and enzyme-histochemical and physiological properties of a novel fast-twitch motor unit type. Am. J. Physiol. Cell Physiol. 261(1), C93-C101 (1991).
51. Wang Y-X, Zhang C-L, Yu RT et al. Regulation of muscle fiber type and running endurance by PPAR&δ. PLoS Biol. 2(10), e294 (2004).
52. Lin J, Wu H, Tarr PT et al. Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres. Nature 418(6899), 797-801 (2002).
53. Baar KEIT, Wende AR, Jones TE et al. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J. 16(14), 1879-1886 (2002).
54. Arany Z, Lebrasseur N, Morris C et al. The transcriptional coactivator PGC-1β drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab. 5(1), 35-46 (2007).
55. Patti ME, Butte AJ, Crunkhorn S et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl Acad. Sci. USA 100(14), 8466-8471 (2003).
56. Russell AP, Feilchenfeldt J, Schreiber S et al. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-γ coactivator-1 and peroxisome proliferator-activated receptor-α in skeletal muscle. Diabetes 52(12), 2874-2881 (2003).
57. Kramer DK, Ahlsen M, Norrbom J et al. Human skeletal muscle fibre type variations correlate with PPAR α, PPAR δ and PGC-1 α mRNA. Acta Physiol. (Oxford) 188(3-4), 207-216 (2006).
58. Seth A, Steel JH, Nichol D et al. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metab. 6(3), 236-245 (2007).
59. St-Pierre J, Drori S, Uldry M et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127(2), 397-408 (2006).
60. Weydt P, Pineda VV, Torrence AF et al. Thermoregulatory and metabolic defects in Huntingtons disease transgenic mice implicate PGC-1α in Huntingtons disease neurodegeneration. Cell Metab. 4(5), 349-362 (2006).
61. Vianna CR, Huntgeburth M, Coppari R et al. Hypomorphic mutation of PGC-1β causes mitochondrial dysfunction and liver insulin resistance. Cell Metab. 4(6), 453-464 (2006).
62. Sladek R, Bader JA, Giguere V. The orphan nuclear receptor estrogen-related receptor α is a transcriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene. Mol. Cell. Biol. 17(9), 5400-5409 (1997).
63. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1(6), 361-370 (2005).
64. Puigserver P, Rhee J, Lin J et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARγ coactivator-1. Mol. Cell 8(5), 971-982 (2001).
65. Cao W, Daniel KW, Robidoux J et al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol. Cell. Biol. 24(7), 3057-3067 (2004).
66. Christian M, White R, Parker MG. Metabolic regulation by the nuclear receptor corepressor RIP140. Trends Endocrinol. Metab. 17(6), 243-250 (2006).
67. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-α activators. Hypertension 46(5), 1086-1092 (2005).
68. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351(11), 1106-1118 (2004).
69. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007).
70. Debevec D, Christian M, Morganstein D et al. Receptor interacting protein 140 regulates expression of uncoupling protein 1 in adipocytes through specific peroxisome proliferator activated receptor isoforms and estrogen-related receptor α. Mol. Endocrinol. 21(7), 1581-1592 (2007).
71. Fievet C, Fruchart J-C, Staels B. PPARα and PPARγ dual agonists for the treatment of Type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 6(6), 606-614 (2006).
72. Kendall DM, Rubin CJ, Mohideen P et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29(5), 1016-1023 (2006).
73. Nissen SE, Wolski K, Topol EJ. Effect of Muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 294(20), 2581-2586 (2005).
74. Seth A, Steel JH, Nichol D et al. The transcriptional co-repressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metab. 6(3), 236-245 (2007).
75. Wende AR, Huss JM, Schaeffer PJ, Giguere V, Kelly DP. PGC-1α coactivates PDK4 gene expression via the orphan nuclear receptor ERRα: a mechanism for transcriptional control of muscle glucose metabolism. Mol. Cell. Biol. 25(24), 10684-10694 (2005).
76. Zhang Y, Ma K, Sadana P et al. Estrogen-related receptors stimulate pyruvate dehydrogenase kinase isoform 4 gene expression. J Biol. Chem. 281(52), 39897-39906 (2006).
77. Mazzucotelli A, Viguerie N, Tiraby C et al. The transcriptional coactivator PGC-1α and the nuclear receptor PPARα control the expression of glycerol kinase and metabolism genes independently of PPARγ activation in human white adipocytes. Diabetes 56(10), 2467-2475 (2007).
78. Koves TR, Li P, An J et al. Peroxisome proliferator-activated receptor-γ co-activator 1α-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J. Biol. Chem. 280(39), 33588-33598 (2005).